Beta-globin mRNA increases rapidly during erythropoietin treatment

Recombinant human erythropoietin (r-HuEpo) has an important role in the treatment of anaemic patients. Because of the high cost of r-HuEpo treatment, an early indicator of whether a patient is responding to the therapy would be valuable. Although measurement of gene expression is a promising new tool, it has not yet been established in clinical practice. The response pattern of a possible new marker, beta-globin mRNA, is compared with reticulocyte count, levels of haemoglobin, transferrin receptor and ferritin after r-HuEpo treatment. Eight healthy volunteers were stimulated with erythropoietin three times a week for four weeks and compared with five untreated control subjects. Blood samples were collected before each erythropoietin injection. Quantitative measurement of beta-globin mRNA was performed by poly(A) selection onto a manifold plastic support, coated with oligo(dT). The mRNA was reverse transcribed, followed by quantitative analysis using PCR via the 5' nuclease assay. The individuals treated with rHuEpo showed a more distinct increase in beta-globin mRNA levels than all other laboratory measurements. Beta-globin mRNA levels are therefore promising as a marker for the response to treatment with Epo.

Barbany, G. (författare)
Landegren, U. (författare)
Birgegård, Gunnar,1944-Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi (författare)
Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Ingår i:Scandinavian Journal of Clinical and Laboratory Investigation63:3, s. 239-2450036-55131502-7686

Av författaren/redakt...: Hagberg, A.; Barbany, G.; Landegren, U.; Birgegård, Gunna ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.